Market research
NERV Minerva Neurosciences Inc
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 112M
- P/E ratio
- Not available
- Analyst target
- 10.3333
- Dividend yield
- Not available
- Beta
- -0.12
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 112M
- P/E ratio
- Not available
- Analyst target
- 10.3333
- Dividend yield
- Not available
- Beta
- -0.12
About
About Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Research context
Minerva Neurosciences Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the NERV discussion.
5 years, 7 months ago
Minerva Neurosciences, Inc is currently in a long term downtrend where the price is trading 24.1% below its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.9.
Minerva Neurosciences, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 75.5% to $-7M since the same quarter in the previous year.
Finally, its free cash flow grew by 49.5% to $-7M since the same quarter in the previous year.
Based on the above factors, Minerva Neurosciences, Inc gets an overall score of 3/5.